Emergent BioSolutions acquires opioid overdose company
Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire opioid overdose and addiction company Adapt Pharma Ltd. (Dublin, Ireland) for $635 million up front, comprising $575 million in cash and $60 million in stock. Adapt shareholders are also eligible for $100 million in sales milestones.
According to BioCentury's BCIQ database, the move is Emergent's first in the opioid overdose space...